Level 9, Suite 1, 68 Pitt Street,
Sydney, NSW, 2000, Australia

+61 (02) 8964 7401

Social Media

Media Centre

In the News

Alzheimer’s trial targeting stress hormone
The Daily Edition – 10 May 2017


Australian Firm Treads New Path On Alzheimer’s
The Australian Financial Review – 10 May 2017


Professor Colin Masters receives Australia Day Honours


Research Paper: Selection and early clinical evaluation of the brain-penetrant 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor UE2343 (Xanamem™) published in BJP

The world love melbourne is a blog that recently wrote about Actinoge's Understanding Alzheimer's eventThe World Loves Melbourne Article on ACW

IT Wire covers ACW with an article on its landmark researchAussie Company Developing ‘Landmark’ Drug

Herald Sun coverage of Actinogen's drug to be trialledAustralian Drug to be Trialled – Herald Sun

NextBiotech published an article about ACW starting a phase II trialACW Starts a Phase II Trial – NextBiotech

Alzheimer's Research offers hopeAlzheimer’s research offers hope

Victorian trial to treat early-stage Alzheimer's by reducing brain's stress hormone levelsVictorian trial to treat early-stage Alzheimer’s by reducing brain’s stress hormone levels

BusinessWire article on Actinogen MedicalBusinessWire Coverage on Actinogen Landmark Research

FinFeedFDA Feedback puts Actinogen’s phase II trial one step closer to US approval

NextBiotechMulti-Billion Alzheimer’s Drug Development Boom Underway: ACW Well Positioned in Phase II Trials

Biotech DailyDaily news on ASX-listed biotechnology companies

Ex Pfizer VP to Repeat Market Topping Drug Development with this ASX Stock? Ex Pfizer VP to Repeat Market Topping Drug
Development with this ASX stock?

thumbnail of Alzheimer's cure behind the boom in brain science

Alzheimer’s cure behind the boom in brain science

Undervalued Biotech Entering Phase II Trial for Alzheimer's Disease Undervalued Biotech Entering Phase II Trial for Alzheimer’s Disease

Wholesale InvestorActinogen Receives US FDA Feedback

Actinogen discusses Xanamem Phase 1 resultsActinogen discusses Xanamem Phase 1 results

Actinogen Medical readies to release Phase I clinical trial results

Actinogen readies to reveal clinical data

Actinogen Medical raises $10M for Alzheimer's Drug trialActinogen Medical raises $10M for Alzheimer’s drug trial

Actinogen Medical on Track with Alzheimer's DrugActinogen Medical on track with Alzheimer’s Drug

Social Media


Dr. Bill Ketelbey


Corporate Events


ASX/FNN CEO Sessions – November (BNE, AUS)

AusBiotech Invest Conference – October (MEL, AUS)

AusBiotech Conference – October (MEL, AUS)

Microcap Investment Conference – October ( MEL, AUS)

BioShares Biotechnology Summit – July (ZQN, NZ)

Canary News Networks – July (SYD & MEL, AUS)

ASX/FNN Investor Series – June (PER, AUS)

ASX/FNN Spotlight Series – May (SIN & HKG)

ASX/FNN Investor Series – April (SYD, AUS)

ADI Conference – April (PER, AUS)

AC4R Conference – April (PER, AUS)

ADPD Conference – March (NCE, France)

JP Morgan – January (SFO, USA)


AusBiotech 2016 – October (MEL, AUS)

BioShares Biotechnology Summit – July (ZQN, NZ)

AAIC – July (YYZ, Canada)

AC4R Conference – May (CNS, AUS)

ARCS Scientific Congress – May (SYD, AUS)

BioEquity – May (CPH, Denmark)

WI: Small Cap Showcase – May (SYD)


We are a supporter of Wipeout Dementia and Friend of The Dementia Momentum.

Subscribe to our newsletter

Are you an Investor?  Yes